Clinical Trial Update: An Open Label Field Study of Anthim (Obiltoxaximab) in Subjects Exposed to B. Anthracis [Phase 4]

View source ↗

Summary

Open-label Phase 4 study evaluating Anthim (obiltoxaximab) in individuals exposed to Bacillus anthracis (anthrax).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anthrax
• Infection Bacterial

Drugs mentioned

• ANTHIM (obiltoxaximab)

Snippet

Sponsor: Elusys Therapeutics | Conditions: Infection, Bacterial, Anthrax | Phase 4 | Status: UNKNOWN